Therapy News and Research

RSS

OncoSynergy's OS2966 receives FDA orphan drug designation for treatment of glioblastoma

OncoSynergy announced today that the FDA Office of Orphan Products Development has granted orphan drug designation for the investigational drug candidate OS2966, a neutralizing anti-CD29 monoclonal antibody, for the treatment of glioblastoma, the most common and deadliest primary adult brain tumor.

12 Aug 2014

Feist-Weiller, Caris Life Sciences partner to offer breakthrough technology to cancer patients

Doctors at the LSU Health Shreveport Feist-Weiller Cancer Center will now have access to innovative, precision-medicine technology that determines the unique biological characteristics of each individual patient's cancer tumor.

12 Aug 2014

Research: First effective web-based treatment for bipolar disorder

The first effective web-based treatment for Bipolar Disorder based on the latest research evidence has been developed by psychologists.

12 Aug 2014

Sanofi, PATH announce delivery of first large-scale batches of antimalarial treatments

Sanofi and PATH today announced the delivery of the first large-scale batches of antimalarial treatments manufactured with a new semisynthetic artemisinin derivative to malaria-endemic countries in Africa.

12 Aug 2014

First Edition: August 12, 2014

Today's headlines include stories about how the federal government's experience with healthcare.gov has led to the creation of the U.S. Digital Service.

12 Aug 2014

Bee, snake, scorpion venom could form basis of new generation of cancer-fighting drugs

Bee, snake or scorpion venom could form the basis of a new generation of cancer-fighting drugs, scientists will report here today.

12 Aug 2014

Clinical trial to investigate safety of neural stem cell transplantation in patients with spinal cord injuries

Researchers at the University of California, San Diego School of Medicine have launched a clinical trial to investigate the safety of neural stem cell transplantation in patients with chronic spinal cord injuries.

12 Aug 2014

Researchers discover how arginine starvation specifically kills cancer cells

Researchers at UC Davis, City of Hope, Taipai Medical University and National Health Research Institutes in Taiwan have discovered how a drug that deprives the cells of a key amino acid specifically kills cancer cells.

12 Aug 2014

First peer-reviewed comprehensive expert guidance on the use of neurostimulation for pain

Reflecting groundbreaking international consensus regarding a group of rapidly evolving medical interventions for chronic pain, the International Neuromodulation Society announced it will soon publish the first peer-reviewed comprehensive expert guidance on the appropriate use of neurostimulation for pain.

12 Aug 2014

Seven physicians receive ASTRO grants to advance radiation oncology research

The American Society for Radiation Oncology has selected seven leading physicians to receive a total of $675,000 in awards and grants to advance radiation oncology research. The ASTRO Junior Faculty Career Research Training Award, the ASTRO Residents/Fellows in Radiation Oncology Research Seed Grant and the ASTRO/Radiation Oncology Institute Comparative Effectiveness Research Award will fund studies in radiation and cancer biology, radiation physics, translational research, outcomes/health services research and comparative effectiveness research within radiation oncology.

12 Aug 2014

Skilled Healthcare Group Q2 2014 revenue decreases 1.5% to $207 million

Skilled Healthcare Group, Inc. today announced its consolidated financial operating results for the three and six month period ended June 30, 2014.

12 Aug 2014

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts believe a molecule in parasitic worms could help explain why worm infections can effectively treat a range of autoimmune diseases, including multiple sclerosis, psoriasis, rheumatoid arthritis and lupus.

12 Aug 2014

Oncothyreon acquires Alpine Biosciences to enable targeted delivery of multiple therapeutic agents

Oncothyreon Inc., a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it has acquired Alpine Biosciences, Inc., of Seattle, Washington, a privately held biotechnology company developing protocells, a nanoparticle platform technology designed to enable the targeted delivery of multiple therapeutic agents, including nucleic acids, proteins, peptides and small molecules.

12 Aug 2014

Novogen receives funding support to commence studies in muscular dystrophy

The Australian biotechnology company, Novogen Limited today announced receipt of funding from the FSHD Global Research Foundation as part of the Company’s efforts to find effective treatments for a range of musculo-degenerative diseases including facioscapulohumeral dystrophy (FSHD).

11 Aug 2014

$Sacral magnetic stimulation effective in refractory stress incontinence$

Sacral magnetic stimulation effective in refractory stress incontinence

Sacral magnetic stimulation may be an effective treatment for stress urinary incontinence in women whose symptoms are refractory to standard therapies, a clinical trial suggests.

11 Aug 2014

Opioid compliance checklist shows promise for chronic pain management

Researchers have developed a brief and simple checklist that clinicians can use to monitor opioid adherence among people with chronic pain.

11 Aug 2014

Antimalarial agent chloroquine normalizes abnormal tumor blood vessels

A recent study by investigators at VIB and KU Leuven has demonstrated that chloroquine also normalizes the abnormal blood vessels in tumors. This blood vessel normalization results in an increased barrier function on the one hand -- thereby blocking cancer cell dissemination and metastasis -- and in enhanced tumor perfusion on the other hand, which increases the response of the tumor to chemotherapy.

11 Aug 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013.

11 Aug 2014

ResMed releases new forward-thinking connected care solution for SDB treatment

ResMed today announced Air Solutions, a new forward-thinking connected care solution for treating sleep-disordered breathing that can benefit all stakeholders in the care continuum. The ResMed Air Solutions platform has data-driven components that span from diagnosis to treatment, compliance management and patient engagement.

From ResMed Corp 11 Aug 2014

Sanofi, MannKind sign licensing agreement to develop and commercialize Afrezza Inhalation Powder

Sanofi and MannKind Corporation announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes.

11 Aug 2014

Therapy News and Research

OncoSynergy's OS2966 receives FDA orphan drug designation for treatment of glioblastoma

Feist-Weiller, Caris Life Sciences partner to offer breakthrough technology to cancer patients

Research: First effective web-based treatment for bipolar disorder

Sanofi, PATH announce delivery of first large-scale batches of antimalarial treatments

First Edition: August 12, 2014

Bee, snake, scorpion venom could form basis of new generation of cancer-fighting drugs

Clinical trial to investigate safety of neural stem cell transplantation in patients with spinal cord injuries

Researchers discover how arginine starvation specifically kills cancer cells

First peer-reviewed comprehensive expert guidance on the use of neurostimulation for pain

Seven physicians receive ASTRO grants to advance radiation oncology research

Skilled Healthcare Group Q2 2014 revenue decreases 1.5% to $207 million

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Oncothyreon acquires Alpine Biosciences to enable targeted delivery of multiple therapeutic agents

Novogen receives funding support to commence studies in muscular dystrophy

Sacral magnetic stimulation effective in refractory stress incontinence

Opioid compliance checklist shows promise for chronic pain management

Antimalarial agent chloroquine normalizes abnormal tumor blood vessels

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

ResMed releases new forward-thinking connected care solution for SDB treatment

Sanofi, MannKind sign licensing agreement to develop and commercialize Afrezza Inhalation Powder

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News